admin – Page 4381 – Get News Story

NEOVIVA Unveils Switzerland’s First Luxury Addiction Clinic With a Results Guarantee

The clinic, located on the shores of Lake Lucerne, combines evidence-based therapies with innovative treatments and offers a unique results-based guarantee to support clients’ long-term recovery.

NEOVIVA, a luxury rehab clinic located on the shores of Lake Lucerne, has launched Switzerland’s first addiction treatment center offering a results-based guarantee. This marks a significant development in the treatment of substance abuse and behavioral addiction, particularly within the high-end rehab segment.

The NEOVIVA Guarantee underscores the clinic’s commitment to long-term recovery. It offers clients who relapse within a year of completing their initial program up to four weeks of intensive treatment at no cost, subject to specific conditions. This initiative sets NEOVIVA apart in the addiction recovery industry.

“Our goal is not only to help clients overcome their challenges but to support them in sustaining recovery over the long term,” said founders Oliver Neubert and Fenina Erpf, recognized experts in addiction treatment and mental health. “The NEOVIVA Guarantee reflects our confidence in our programs and ensures clients feel supported every step of the way.”

NEOVIVA adopts a personalized approach to addiction treatment, addressing issues such as substance abuse, behavioral addiction, and mental health disorders. The clinic operates within a functioning hotel, providing a real-world setting to help clients transition back into their daily lives. Its evidence-based practices include therapies like repetitive Transcranial Magnetic Stimulation (rTMS), mindfulness training, and body-centered activities.

Licensed by the Swiss Department of Health, the clinic integrates traditional and innovative treatments designed to meet the diverse needs of its clients. Programs address conditions ranging from alcohol and drug addiction to dual-diagnosis disorders, including anxiety, depression, PTSD, and OCD. A multilingual team of specialists ensures tailored care that aligns with each client’s unique circumstances and recovery goals.

The clinic’s location on Lake Lucerne offers a serene and private environment, fostering healing and reflection. With a maximum of five clients at a time, NEOVIVA provides individualized attention and privacy, catering to those seeking discretion in their recovery journey. Clients can even bring their dogs to support them during their treatment.

“The journey to recovery is about resilience, not perfection,” said Neubert and Erpf. “We are committed to supporting our clients through every phase of their healing process, emphasizing that setbacks are part of progress, not failure.”

Upon completion of NEOVIVA’s Signature Programme of at least four weeks, clients get 30 weeks of Continuing Care, including complimentary online support groups and optional refresher sessions, ensuring continuity of care. These offerings aim to provide a comprehensive support system that extends well beyond the initial treatment phase.

The launch of NEOVIVA’s results-based guarantee has made the clinic a leader in luxury rehab services. It blends evidence-based therapies with innovative practices to redefine addiction treatment and recovery.

For more information about NEOVIVA’s programs and the NEOVIVA Guarantee, visit neoviva.com or contact their team directly.

Media Contact
Company Name: NEOVIVA
Contact Person: Fenina Erpf
Email: Send Email
Country: Switzerland
Website: https://neoviva.com/

Nitin Khanna’s Mindful Innovation: How Legacy Industries Are Adapting to Modern Values

Nitin Khanna, Portland, Oregon

Entrepreneur and innovator Nitin Khanna is raising awareness about the potential to revitalize traditional industries, particularly in health, wellness, and premium spirits. According to Khanna, industries with deep-rooted traditions are poised for meaningful transformation. “It’s not about discarding the past; it’s about elevating it to meet modern needs,” he explains.

As global markets evolve, consumer expectations are changing rapidly. The wellness industry, for example, has shifted from one-size-fits-all solutions to highly personalized experiences. According to the Global Wellness Institute, the global wellness economy is projected to reach $7 trillion by 2025, driven by demand for integrative, tech-enabled solutions.

“Today’s consumers want products and services that fit their unique lifestyles,” says Khanna. “They’re not just looking for convenience; they want authenticity, transparency, and trust. Brands that fail to meet these expectations risk being left behind.”

The rise of wearable technology, AI-driven health platforms, and alternative therapies underscores this trend. However, Khanna emphasizes that innovation alone is not enough. “Consumers need to trust the mission behind the brand. Transparency and ethical practices are key to building that trust.”

In the premium spirits sector, the story is similar. While deeply rooted in history, this industry is being reshaped by a new generation of consumers who value quality and sustainability. According to the Distilled Spirits Council of the U.S., sales of high-end and super-premium spirits grew by over 40% in the past five years, reflecting a strong preference for artisanal craftsmanship and meaningful brand narratives.

“Modern consumers don’t just want a great product; they want a great story,” explains Khanna. “They want to know where it comes from, how it’s made, and the values behind the brand. This shift presents incredible opportunities for businesses willing to embrace innovation while staying true to their roots.”

Interestingly, Khanna points out an emerging intersection between wellness and spirits. The rise of low-alcohol and alcohol-free options, along with spirits infused with botanicals and functional ingredients, reflects a growing trend toward mindful consumption.

“Both wellness and spirits are about enhancing life experiences,” Khanna says. “Wellness focuses on balance and mindfulness, while spirits celebrate moments of joy and connection. Together, they represent a more intentional way of living.”

Khanna believes that transforming these industries isn’t just about meeting consumer demand—it’s about creating meaningful impact. “Success isn’t just measured in profits,” he explains. “It’s about resonating deeply with people’s lives while staying true to your values.”

By blending innovation with tradition, industries like wellness and premium spirits are undergoing remarkable transformations. Entrepreneurs, Khanna asserts, have a unique opportunity to shape the future of these sectors while leaving a legacy of authenticity and purpose.

Media Contact
Contact Person: Nitin Khanna
Email: Send Email
City: Portland
State: Oregon
Country: United States
Website: https://www.nitinkhannaportland.com/

Short Bowel Syndrome Pipeline Trends 2024: Clinical Trials, Analysis of Clinical Trials, Therapies, MOA, ROA, and Developments by DelveInsight | Zealand Pharma, Ironwood Pharma, Hanmi Pharma, Shire

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Short Bowel Syndrome pipeline constitutes 18+ key companies continuously working towards developing 20+ Short Bowel Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Short Bowel Syndrome Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Short Bowel Syndrome Market.

The Short Bowel Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Short Bowel Syndrome Pipeline Report:

Companies across the globe are diligently working toward developing novel Short Bowel Syndrome treatment therapies with a considerable amount of success over the years.
Short Bowel Syndrome companies working in the treatment market are Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others, are developing therapies for the Short Bowel Syndrome treatment

Emerging Short Bowel Syndrome therapies in the different phases of clinical trials are- Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others are expected to have a significant impact on the Short Bowel Syndrome market in the coming years.
In October 2024, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a company focused on gastrointestinal healthcare, will present new results at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course. The findings come from subgroup analyses of the primary endpoint in the pivotal Phase III STARS trial, assessing apraglutide’s treatment effect in adults with short bowel syndrome with intestinal failure (SBS-IF). The data, which will be shared in an oral presentation on October 29 from 8:30 am – 8:40 am ET, show that apraglutide demonstrated a consistent treatment effect across various subgroups, including gender, age, body weight, region, race, ethnicity, and SBS characteristics, such as the length of remnant bowel. These results further support the previously reported positive data from the Phase III trial.
In May 2024, Jaguar Health, Inc. (NASDAQ: JAGX) announced that its subsidiary companies, Napo Pharmaceuticals and Napo Therapeutics, have submitted a Clinical Trial Application (CTA) to the health authorities in Italy and Germany to initiate a Phase 2 clinical trial for Jaguar’s novel plant-based prescription drug, crofelemer, for treating short bowel syndrome (SBS) with intestinal failure in adults. Additionally, Napo Therapeutics has submitted a CTA to AIFA, the Italian health authority, to conduct a clinical trial for pediatric patients with microvillus inclusion disease (MVID). The approval process for this trial is also underway in the United Arab Emirates with Dubai Health. The MVID clinical trial is being conducted under an active US Investigational New Drug (IND) application.
In February 2024, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a company specializing in gastrointestinal healthcare, has unveiled promising top-line outcomes from its pivotal Phase III STARS trial. This trial assessed the effectiveness and safety of subcutaneous apraglutide administered once weekly in reducing the dependency on parenteral support (PS) in adult patients diagnosed with short bowel syndrome with intestinal failure (SBS-IF). SBS-IF is a rare and severe condition resulting in organ failure, where patients rely on PS. Approximately 18,000 adult patients in the United States, Europe, and Japan are affected by this condition. Following these findings, Ironwood intends to submit a new drug application (NDA) and other regulatory documents for apraglutide aimed at treating adult SBS patients reliant on PS.

Short Bowel Syndrome Overview

Short Bowel Syndrome (SBS) is a condition that occurs when a person has lost a significant portion of their small intestine, either due to surgery or disease. This results in the inability of the body to absorb enough nutrients and fluids from food. The severity of SBS depends on how much of the small intestine is removed and its ability to adapt. Symptoms include diarrhea, dehydration, malnutrition, and weight loss. SBS is typically managed through dietary changes, nutritional supplements, and in some cases, intravenous feeding or medications to improve nutrient absorption.

Get a Free Sample PDF Report to know more about Short Bowel Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/short-bowel-syndrome-pipeline-insight

Emerging Short Bowel Syndrome Drugs Under Different Phases of Clinical Development Include:

Glepaglutide: Zealand Pharma
Apraglutide: Ironwood Pharmaceuticals
HM15912: Hanmi Pharmaceutical
Teduglutide: Shire
Pancreatic Enzyme: AbbVie
HM15912 Active: Hanmi Pharma
Somatropin: EMD Serono
ZP1848: Zealand Pharma
FE203799: VectivBio AG
Clinolipid: Baxter Healthcare

Short Bowel Syndrome Route of Administration

Short Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Short Bowel Syndrome Molecule Type

Short Bowel Syndrome Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Short Bowel Syndrome Pipeline Therapeutics Assessment

Short Bowel Syndrome Assessment by Product Type
Short Bowel Syndrome By Stage and Product Type
Short Bowel Syndrome Assessment by Route of Administration
Short Bowel Syndrome By Stage and Route of Administration
Short Bowel Syndrome Assessment by Molecule Type
Short Bowel Syndrome by Stage and Molecule Type

DelveInsight’s Short Bowel Syndrome Report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Short Bowel Syndrome product details are provided in the report. Download the Short Bowel Syndrome pipeline report to learn more about the emerging Short Bowel Syndrome therapies

Some of the key companies in the Short Bowel Syndrome Therapeutics Market include:

Key companies developing therapies for Short Bowel Syndrome are – VectivBio AG, 9 Meters Biopharma, Inc., Nutrinia Ltd., Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, Hanmi Pharm.Co., Ltd., and Pharmascience, Inc., and others.

Short Bowel Syndrome Pipeline Analysis:

The Short Bowel Syndrome pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Short Bowel Syndrome with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Short Bowel Syndrome Treatment.
Short Bowel Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Short Bowel Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Short Bowel Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Short Bowel Syndrome drugs and therapies

Short Bowel Syndrome Pipeline Market Strengths

In the treatment of short bowel syndrome, GLP-2 and the long-acting GLP-2 analog are effective in improving fluid absorption. Recent clinical trials demonstrate that this can translate into meaningful reductions in parenteral nutrition requirements.
Current treatments are effective in relieving the symptoms and improving the quality of life of the patients

Short Bowel Syndrome Pipeline Market Opportunities

Several organizations are actively working to provide information and increase awareness of such disorders.
There are less treatment options for Short bowel syndrome which opens a platform of new therapies to boost the market of Short bowel syndrome

Scope of Short Bowel Syndrome Pipeline Drug Insight

Coverage: Global
Key Short Bowel Syndrome Companies: Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others
Key Short Bowel Syndrome Therapies: Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others
Short Bowel Syndrome Therapeutic Assessment: Short Bowel Syndrome current marketed and Short Bowel Syndrome emerging therapies
Short Bowel Syndrome Market Dynamics: Short Bowel Syndrome market drivers and Short Bowel Syndrome market barriers

Request for Sample PDF Report for Short Bowel Syndrome Pipeline Assessment and clinical trials

Table of Contents

1. Short Bowel Syndrome Report Introduction

2. Short Bowel Syndrome Executive Summary

3. Short Bowel Syndrome Overview

4. Short Bowel Syndrome- Analytical Perspective In-depth Commercial Assessment

5. Short Bowel Syndrome Pipeline Therapeutics

6. Short Bowel Syndrome Late Stage Products (Phase II/III)

7. Short Bowel Syndrome Mid Stage Products (Phase II)

8. Short Bowel Syndrome Early Stage Products (Phase I)

9. Short Bowel Syndrome Preclinical Stage Products

10. Short Bowel Syndrome Therapeutics Assessment

11. Short Bowel Syndrome Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Short Bowel Syndrome Key Companies

14. Short Bowel Syndrome Key Products

15. Short Bowel Syndrome Unmet Needs

16 . Short Bowel Syndrome Market Drivers and Barriers

17. Short Bowel Syndrome Future Perspectives and Conclusion

18. Short Bowel Syndrome Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Short Bowel Syndrome Pipeline Trends 2024: Clinical Trials, Analysis of Clinical Trials, Therapies, MOA, ROA, and Developments by DelveInsight | Zealand Pharma, Ironwood Pharma, Hanmi Pharma, Shire

Neville Voss Advocates for Quality and Sustainability in Solar Energy

Neville Voss, Hampshire, United Kingdom

Renewable Energy Leader Highlights the Need for High Standards and Scalable Solutions Amid Growing Global Demand

Neville Voss, a renowned entrepreneur and renewable energy leader, is calling for increased attention to quality and sustainability in large-scale solar energy projects. As global solar capacity is projected to grow by 20% annually, ensuring high standards in installations has become a pressing issue for the renewable energy sector. Voss, known for his innovative leadership, is raising awareness about how quality assurance and scalable solutions can drive both customer satisfaction and climate impact.

“Solar energy is critical in the fight against climate change, but growth without quality undermines its potential,” says Voss. “Mistakes in installations not only cost time and money but also erode trust in renewable energy solutions. Precision and sustainability must go hand in hand.”

The renewable energy market is booming, with global solar energy capacity expected to exceed 1 terawatt by 2025, according to the International Energy Agency (IEA). However, a 2021 McKinsey report found that errors in solar installations increase project costs by 15-20%, highlighting the need for meticulous quality assurance.

Voss emphasizes the role of technology in improving installation outcomes. Tools like AI-powered drones and IoT-enabled sensors enable real-time monitoring of solar systems, ensuring early detection of potential issues. “Leveraging these technologies allows us to balance speed with precision, which is essential for scaling operations responsibly,” he explains.

Sustainability is another key focus for Voss. He notes that large-scale solar installations significantly contribute to carbon reduction goals, with solar energy displacing over 1.5 billion metric tons of CO₂ emissions annually. “Every properly installed panel is a step toward a cleaner future,” he adds. “But to maximize this impact, we need to prioritize sustainable practices at every stage of the process.”

Customer-centricity also plays a central role in Voss’s advocacy. He stresses the importance of aligning solar operations with the needs of homeowners and businesses, ensuring a seamless and satisfying transition to renewable energy. “When customers trust that their systems are reliable and efficient, they become advocates for solar, amplifying its adoption,” he says.

Through mentorship and team development, Voss continues to inspire the next generation of solar leaders. By embedding values of quality, sustainability, and innovation, he is shaping an industry poised to meet the demands of a greener future.

“Renewable energy isn’t just about technology—it’s about people, precision, and purpose,” concludes Voss. “If we maintain high standards and stay committed to sustainability, we can meet the urgent needs of our planet and its people.”

Media Contact
Contact Person: Neville Voss
Email: Send Email
City: Hampshire
State: London
Country: United Kingdom
Website: https://nevillevoss.com/

Restrictive Cardiomyopathy Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Array Biopharma, AstraZeneca, Sanofi Aventis U.S LLC, Roche, Merck

DelveInsight’s “Restrictive Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Restrictive Cardiomyopathy, historical and forecasted epidemiology as well as the Restrictive Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Restrictive Cardiomyopathy, offering comprehensive insights into the Restrictive Cardiomyopathy revenue trends, prevalence, and treatment landscape. The report delves into key Restrictive Cardiomyopathy statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Restrictive Cardiomyopathy therapies. Additionally, we cover the landscape of Restrictive Cardiomyopathy clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Restrictive Cardiomyopathy treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Restrictive Cardiomyopathy space.

To Know in detail about the Restrictive Cardiomyopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Restrictive Cardiomyopathy Market Forecast

Some of the key facts of the Restrictive Cardiomyopathy Market Report:

The Restrictive Cardiomyopathy market size was valued ~USD 26 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In the 7MM, RASI (ACEi/ARB) accounted for the largest market share, generating approximately USD 11.03 million in 2023.
In 2023, the US dominated the 7MM market, accounting for 69% of the total share, followed by the EU4 and the UK. This trend is expected to grow further during the forecast period (2024–2034).
In 2023, the EU4 and the UK accounted for approximately 30% of the total market share within the 7MM.

Key Restrictive Cardiomyopathy Companies: Array Biopharma Inc., AstraZeneca, Sanofi Aventis U.S LLC, Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., Capricor Therapeutics, MyoKardia, Janssen Products, GlaxSoSmithKline, Teva Pharmaceuticals, Cipla, Sun Pharmaceuticals, and others.
Key Restrictive Cardiomyopathy Therapies: Camzyos™, and others
The Restrictive Cardiomyopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Restrictive Cardiomyopathy pipeline products will significantly revolutionize the Restrictive Cardiomyopathy market dynamics.
It is estimated that there were 73,000 diagnosed prevalent cases of Restrictive Cardiomyopathy in the 7MM in 2023.
According to estimates, there were 36,000 diagnosed prevalent cases of Restrictive Cardiomyopathy in the United States in 2023, with the number expected to rise over the forecast period.
Estimates indicate that the total diagnosed prevalent cases of Restrictive Cardiomyopathy in the EU4 and the UK reached 35,000 in 2023. Among the EU4 countries, Germany reported the highest proportion of cases, while Spain had the lowest.
Estimates indicate that the number of Restrictive Cardiomyopathy cases in Japan was around 1,000 in 2023, with projections suggesting a decline by 2034.

Restrictive Cardiomyopathy Overview

Restrictive Cardiomyopathy (RCM) is a rare type of heart disease where the walls of the heart’s ventricles become stiff but not thickened. This stiffness limits the heart’s ability to fill with blood during diastole (relaxation phase), leading to reduced blood flow and efficiency. Common causes include conditions like amyloidosis, sarcoidosis, or other infiltrative or fibrotic diseases. Symptoms often include fatigue, shortness of breath, swelling in the legs, and irregular heartbeats. Diagnosis typically involves imaging tests, such as echocardiography or MRI, and sometimes biopsy. Treatment focuses on managing symptoms and underlying causes.

Get a Free sample for the Restrictive Cardiomyopathy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/restrictive-cardiomyopathy-market

Restrictive Cardiomyopathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Restrictive Cardiomyopathy Epidemiology Segmentation:

The Restrictive Cardiomyopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Restrictive Cardiomyopathy
Prevalent Cases of Restrictive Cardiomyopathy by severity
Gender-specific Prevalence of Restrictive Cardiomyopathy
Diagnosed Cases of Episodic and Chronic Restrictive Cardiomyopathy

Download the report to understand which factors are driving Restrictive Cardiomyopathy epidemiology trends @ Restrictive Cardiomyopathy Epidemiology Forecast

Restrictive Cardiomyopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Restrictive Cardiomyopathy market or expected to get launched during the study period. The analysis covers Restrictive Cardiomyopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Restrictive Cardiomyopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Restrictive Cardiomyopathy Therapies and Key Companies

Camzyos™: Bristol Myers Squibb

Discover more about therapies set to grab major Restrictive Cardiomyopathy market share @ Restrictive Cardiomyopathy Treatment Landscape

Restrictive Cardiomyopathy Market Drivers

Advancements in Diagnostic Techniques
Increasing Awareness
Rising Prevalence of Associated Conditions
Innovative Therapeutic Developments
Supportive Regulatory Environment

Restrictive Cardiomyopathy Market Barriers

Limited Treatment Options
High Cost of Advanced Therapies
Challenges in Early Diagnosis
Low Awareness in Certain Regions
Competition from Generic Drugs

Scope of the Restrictive Cardiomyopathy Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Restrictive Cardiomyopathy Companies: Array Biopharma Inc., AstraZeneca, Sanofi Aventis U.S LLC, Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., Capricor Therapeutics, MyoKardia, Janssen Products, GlaxSoSmithKline, Teva Pharmaceuticals, Cipla, Sun Pharmaceuticals, and others
Key Restrictive Cardiomyopathy Therapies: Camzyos™, and others
Restrictive Cardiomyopathy Therapeutic Assessment: Restrictive Cardiomyopathy current marketed and Restrictive Cardiomyopathy emerging therapies
Restrictive Cardiomyopathy Market Dynamics: Restrictive Cardiomyopathy market drivers and Restrictive Cardiomyopathy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Restrictive Cardiomyopathy Unmet Needs, KOL’s views, Analyst’s views, Restrictive Cardiomyopathy Market Access and Reimbursement

To know more about Restrictive Cardiomyopathy companies working in the treatment market, visit @ Restrictive Cardiomyopathy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Restrictive Cardiomyopathy Market Report Introduction

2. Executive Summary for Restrictive Cardiomyopathy

3. SWOT analysis of Restrictive Cardiomyopathy

4. Restrictive Cardiomyopathy Patient Share (%) Overview at a Glance

5. Restrictive Cardiomyopathy Market Overview at a Glance

6. Restrictive Cardiomyopathy Disease Background and Overview

7. Restrictive Cardiomyopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Restrictive Cardiomyopathy

9. Restrictive Cardiomyopathy Current Treatment and Medical Practices

10. Restrictive Cardiomyopathy Unmet Needs

11. Restrictive Cardiomyopathy Emerging Therapies

12. Restrictive Cardiomyopathy Market Outlook

13. Country-Wise Restrictive Cardiomyopathy Market Analysis (2020–2034)

14. Restrictive Cardiomyopathy Market Access and Reimbursement of Therapies

15. Restrictive Cardiomyopathy Market Drivers

16. Restrictive Cardiomyopathy Market Barriers

17. Restrictive Cardiomyopathy Appendix

18. Restrictive Cardiomyopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Restrictive Cardiomyopathy Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Array Biopharma, AstraZeneca, Sanofi Aventis U.S LLC, Roche, Merck

Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Gastroparesis pipeline constitutes 10+ key companies continuously working towards developing 11+ Gastroparesis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Gastroparesis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastroparesis Market.

The Gastroparesis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Gastroparesis Pipeline Report:

Companies across the globe are diligently working toward developing novel Gastroparesis treatment therapies with a considerable amount of success over the years.
Gastroparesis companies working in the treatment market are CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others, are developing therapies for the Gastroparesis treatment

Emerging Gastroparesis therapies in the different phases of clinical trials are- CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others are expected to have a significant impact on the Gastroparesis market in the coming years.
In September 2024, The US Food and Drug Administration (FDA) has rejected the new drug application (NDA) submitted by Vanda Pharmaceuticals for the use of tradipitant in treating gastroparesis symptoms.

Gastroparesis Overview

Gastroparesis is a condition that affects the stomach’s ability to empty its contents due to nerve damage caused by diabetes. The condition occurs when high blood sugar levels over time damage the vagus nerve, which controls the muscles of the stomach. This results in delayed gastric emptying, causing symptoms like nausea, vomiting, bloating, abdominal pain, and feeling full quickly after eating. It can lead to poor blood sugar control and malnutrition. Treatment focuses on managing blood sugar levels, dietary changes, and medications to improve stomach motility and relieve symptoms.

Get a Free Sample PDF Report to know more about Gastroparesis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/gastroparesis-pipeline-insight

Emerging Gastroparesis Drugs Under Different Phases of Clinical Development Include:

CIN-102: CinDome Pharma, Inc.
Metoclopramide Nasal Spray: Evoke Pharma
Tradipitant: Vanda Pharmaceuticals
IW-9179: Ironwood Pharmaceuticals
TAK-954: Takeda
NG101: Neurogastrx, Inc
CNSA-001: PTC Therapeutics
velusetrag: Theravance Biopharma
GM-611: Chugai Pharma
Camicinal: GlaxoSmithKline
PCS12852: Processa Pharmaceuticals

Gastroparesis Route of Administration

Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Gastroparesis Molecule Type

Gastroparesis Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Gastroparesis Pipeline Therapeutics Assessment

Gastroparesis Assessment by Product Type
Gastroparesis By Stage and Product Type
Gastroparesis Assessment by Route of Administration
Gastroparesis By Stage and Route of Administration
Gastroparesis Assessment by Molecule Type
Gastroparesis by Stage and Molecule Type

DelveInsight’s Gastroparesis Report covers around 11+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Gastroparesis product details are provided in the report. Download the Gastroparesis pipeline report to learn more about the emerging Gastroparesis therapies

Some of the key companies in the Gastroparesis Therapeutics Market include:

Key companies developing therapies for Gastroparesis are – Bayer AG, Cipla Limited, Evoke Pharma, Pfizer Inc., Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Salix Pharmaceuticals, Inc., The Takeda Pharmaceutical, Teva Pharmaceutical, and others.

Gastroparesis Pipeline Analysis:

The Gastroparesis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Gastroparesis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastroparesis Treatment.
Gastroparesis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Gastroparesis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastroparesis market.

Download Sample PDF Report to know more about Gastroparesis drugs and therapies

Gastroparesis Pipeline Market Drivers

Growing prevalence of diabetes, Unmet medical need, Advancements in drug development, Improved awareness and diagnosis, Regulatory support for innovation, are some of the important factors that are fueling the Gastroparesis Market.

Gastroparesis Pipeline Market Barriers

However, Limited effective treatment options, Challenges in drug development, Adverse side effects, High treatment costs, Regulatory challenges, and other factors are creating obstacles in the Gastroparesis Market growth.

Scope of Gastroparesis Pipeline Drug Insight

Coverage: Global
Key Gastroparesis Companies: CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others
Key Gastroparesis Therapies: CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others
Gastroparesis Therapeutic Assessment: Gastroparesis current marketed and Gastroparesis emerging therapies
Gastroparesis Market Dynamics: Gastroparesis market drivers and Gastroparesis market barriers

Request for Sample PDF Report for Gastroparesis Pipeline Assessment and clinical trials

Table of Contents

1. Gastroparesis Report Introduction

2. Gastroparesis Executive Summary

3. Gastroparesis Overview

4. Gastroparesis- Analytical Perspective In-depth Commercial Assessment

5. Gastroparesis Pipeline Therapeutics

6. Gastroparesis Late Stage Products (Phase II/III)

7. Gastroparesis Mid Stage Products (Phase II)

8. Gastroparesis Early Stage Products (Phase I)

9. Gastroparesis Preclinical Stage Products

10. Gastroparesis Therapeutics Assessment

11. Gastroparesis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Gastroparesis Key Companies

14. Gastroparesis Key Products

15. Gastroparesis Unmet Needs

16 . Gastroparesis Market Drivers and Barriers

17. Gastroparesis Future Perspectives and Conclusion

18. Gastroparesis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera

Five Star Painting of Tampa Bay Delivers Residential Painting Services Backed by a Two-Year Warranty

Tampa, FL – Five Star Painting of Tampa Bay provides professional residential painting services across the Tampa Bay area, focusing on both interior and exterior projects. With a range of offerings that include cabinet painting, deck refinishing, and custom interior painting, the company aims to enhance the functionality and aesthetics of local homes. Backed by a two-year warranty, their services are designed to deliver reliable results tailored to meet the specific needs of homeowners.

Comprehensive Services for Home Painting

The company’s professional house painters provide a wide range of services tailored to meet various needs within the home. Each project includes a color consultation to assist homeowners in selecting options that align with their vision and preferences. Services include:

Interior Painting: Application of paint in spaces such as living rooms, bedrooms, kitchens, and bathrooms, with a variety of color and finish options. Services also cover details like ceilings, crown molding, chair rails, and other architectural features.
Exterior Painting: Application of weather-resistant paint coatings to exteriors, including shutters, trim, siding, drywall, and stucco surfaces, to enhance durability and curb appeal.
Cabinet Painting and Refinishing: Repainting and refinishing of kitchen cabinetry, bathroom cabinets, linen closets, and other storage spaces to achieve a refreshed appearance.
Garage Epoxy Flooring: Application of durable epoxy coatings to garage floors, improving both functionality and appearance.
Fence and Deck Painting: Painting and staining of outdoor wood features to protect surfaces and preserve their appearance over time.
Driveway and Concrete Walkway Painting: Coating of concrete surfaces, such as driveways and walkways, to enhance aesthetics and provide added surface protection.

Focus on Quality and Standards

Five Star Painting of Tampa Bay follows established industry practices to ensure each project meets professional standards. The process begins with a detailed consultation to understand the homeowner’s needs, preferences, and budget. Surface preparation, including cleaning, sanding, and pressure washing, addresses common challenges such as staining or discoloration caused by mold or water damage. The painting process includes the application of primer and high-quality paints from trusted brands like Sherwin-Williams and Behr, ensuring a durable and polished finish.

Warranty and Assurance

Five Star Painting of Tampa Bay offers all its residential painting services with a two-year warranty covering materials and workmanship. This warranty includes protection against peeling, cracking, and fading, provided surfaces are properly maintained. The warranty reflects the company’s adherence to industry standards and use of premium materials. Whether it’s residential painting, specialized services such as cabinet painting, fence coating, and deck painting, or projects contributing to broader home improvement and renovation efforts, the warranty provides coverage designed to ensure durable results

Customer-Centric Approach

Five Star Painting of Tampa Bay places emphasis on customer service, maintaining open communication throughout the project. Homeowners can rely on their team for timely completion, attention to detail, and solutions that fit their specific needs.

“We take pride in offering a wide range of painting services to help homeowners achieve their vision and enhance their living spaces,” says Luis Badel, owner of Five Star Painting of Tampa Bay. “Our focus is on providing exceptional customer service, quality work, and reliable solutions that last.”

This commitment to customer satisfaction is reflected in the feedback from homeowners who have worked with the Tampa painting company. Customer Sarah B shared her experience:

“I am so happy with the service from Five Star Painting and highly recommend them to anyone. Luis was very quick at sending me a quote, and we couldn’t beat the price. Two days later, the garage door, front entry door, and two wall lights were painted. Definitely get with this company for a quote. I know I’ll be contacting them again when the next job comes up!”

About Five Star Painting of Tampa Bay

Five Star Painting of Tampa Bay is a locally managed franchise operating under the Neighborly® network, which includes over 225 locations across North America. The company specializes in residential painting services and provides tailored solutions to meet the needs of individual homeowners. Using premium materials and industry-standard techniques, Five Star Painting of Tampa Bay delivers reliable and durable results. Backed by a two-year warranty, the residential painting company is dedicated to serving the Tampa Bay area with professional service and a customer-focused approach.

For more information about residential painting services, contact them at:

Five Star Painting Of Tampa Bay

4230 S MacDill Ave UNIT G, Tampa, FL 33611

(813) 534-6775

Media Contact
Company Name: Five Star Painting of Tampa Bay
Contact Person: Luis M. Badel
Email: Send Email
Phone: (813) 534-6775
Address:4230 S MacDill Ave UNIT G
City: Tampa
State: FL 33611
Country: United States
Website: https://www.fivestarpainting.com/tampa-bay/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Five Star Painting of Tampa Bay Delivers Residential Painting Services Backed by a Two-Year Warranty

Dr. Heather Skeens, Renowned Ophthalmologist and Eye Surgeon, Introduces Riman, the #1 K-Beauty Korean Skincare Brand, to the Tristate Area for Holistic, Anti-Aging Skin Wellness.

“Skincare should be an investment in your health, not a waste of money on products that fail to deliver results,” says Dr. Heather Skeens. “Riman transforms the way we care for our skin, offering luxury, science-backed solutions at an accessible price.”

Dr. Heather Skeens proudly brings Riman, the #1 K-beauty skincare brand, to the tristate area. Known for its innovative, holistic approach to skin wellness, Riman combines science and tradition to deliver exceptional results. As a trusted physician and advocate for self-care, Dr. Heather Skeens is excited to offer these world-renowned products to her community, setting a new standard in skincare excellence. Discover the transformative power of Riman and elevate your skincare routine today.

Renowned physician Dr. Heather Skeens is thrilled to announce the arrival of Riman, the world’s leading K-beauty skincare brand, to the tristate area. Known for its scientific innovation and proven results, Riman products are designed to enhance skin health by stimulating collagen production, reducing signs of aging, and promoting a radiant, youthful glow. This affordable luxury brand is now exclusively available through Dr. Skeens and complements the holistic aesthetic services offered at Bellasee™ Beauty.

Science-Driven Skincare for Visible Results

Riman’s cutting-edge formulations blend advanced skincare science with traditional Korean beauty rituals. The products feature powerful ingredients such as peptides, hyaluronic acid, and plant-based extracts that work synergistically to combat wrinkles, treat acne, and nourish the skin. Backed by clinical research, Riman’s focus on collagen stimulation provides visible results in as little as one week, making it a game-changer for anyone seeking fast and lasting improvements.

Unlike many skin-toxic products on the market, Riman is safe for all ages and skin types, ensuring everyone can achieve healthier, glowing skin without compromise. Whether tackling acne, dullness, or fine lines, Riman delivers real, measurable results.

A Commitment to Holistic Skin Wellness

Dr. Heather Skeens’ approach to beauty goes beyond aesthetics. As a physician dedicated to holistic wellness, she believes that healthy skin reflects overall well-being. At Bellasee™ Beauty, her philosophy combines advanced medical knowledge with self-care solutions to help patients look and feel their best. Introducing Riman aligns perfectly with Dr. Heather Skeens’ mission to offer safe, effective, and toxin-free skincare solutions.

“Skincare should be an investment in your health, not a waste of money on products that fail to deliver results,” says Dr. Heather Skeens. “Riman transforms the way we care for our skin, offering luxury, science-backed solutions at an accessible price.”

Affordable Luxury That Complements Aesthetic Services

Riman products pair seamlessly with Bellasee™ Beauty’s aesthetic treatments, such as RF Microneedling, CoolPeel Laser, and clinical Platelet-Rich Plasma (PRP) Therapy. These treatments, combined with Riman’s anti-aging and collagen-boosting skincare, create a comprehensive regimen for long-term skin rejuvenation.

Dr. Heather Skeens emphasizes that Riman makes luxury skincare attainable without compromising quality. Patients no longer need to overspend on ineffective products. Instead, they can access affordable solutions that work – products that are gentle, nourishing, and life-changing.

Contact Bellasee™ Beauty for Your Riman Experience

To celebrate the launch, Dr. Heather Skeens is offering complimentary mini facials featuring Riman’s transformative products. Call 304.721.4003 today to schedule your consultation and experience the difference. Let Bellasee™ Beauty help you achieve your best skin with the #1 K-beauty brand that’s changing lives worldwide.

Stop wasting money on products that don’t work. Discover the power of Riman and unlock the skin’s potential with affordable luxury that delivers visible results.

For more information go to:

Media Contact
Company Name: Bellasee™ Beauty
Contact Person: Dr. Heather Skeens
Email: Send Email
Phone: (304) 721-4003
Address:300 Technology Dr
City: South Charleston
State: West Virginia 25309
Country: United States
Website: https://bellasee.com/

BountyBay Labs Unveils TradeOS: The Future of Decentralized Transactions with zk-TLS

BountyBay Labs, backed by leading investors TON Ventures and Animoca Brands, announces the launch of TradeOS — a modular, decentralized infrastructure to revolutionize online peer-to-peer (P2P) transactions. By harnessing advanced blockchain and zk-TLS/TEE-TLS technologies, TradeOS eliminates the long-standing issues of high platform fees, low fund efficiency, and data monopolies in traditional monopoly systems, such as eBay and Paypal.

With over 6 million users and 300+ brands already onboard, the TradeOS ecosystem is soaring up in the digital trading space. Its goal is simple yet ambitious: to revolutionise the $4 trillion global P2P transaction market by providing an open, efficient, and scalable blockchain-based trading system for users and businesses alike.

1 (1)

A New Standard: Permissionless, Trust-free Trading with ‘Proof-of-Delivery’

TradeOS makes P2P transactions safer and more efficient with its automated escrow system. Funds are securely held in smart contracts and only released once the Service Provider submits the ‘Proof-of-Delivery.’

This blockchain system eliminates the need for intermediaries: ‘Code-is-law’ — building the trust between parties in a tamper-proof and verifiable way. The ‘Proof-of-delivery’ system not only supports blockchain data, but also leveraging technologies like ZK-TLS and Oracle to interoperate with reliable Web2 data signals — truly break the data silo between Web2 and Web3 world, and operates in a privacy preserving way.

Why ZK-TLS & TEE-TLS Matters

ZK-TLS & TEE-TLS allows TradeOS to securely verify data from Web2 platforms without needing API integrations or centralized permissions. They generate verifiable zk-proofs that can be directly verified by smart contracts. Imagine proving your actions on platforms like Twitter or eBay without revealing sensitive details like your username or passing transaction history.

Target Markets: Unlocking $4 Trillion in Opportunities

TradeOS redefines P2P transaction systems across key high-value markets:

Online Product & Service Trading: escrow the trading for digital products, services, and real-world assets.
Cross-Border B2B Commerce: Stablecoins is a growing popular settlement tool to overcome currency conversion inefficiencies. TradeOS is the blockchain-native escrow system for seamless and low-cost international transactions.
Influencer Marketing: allow influencer auto-management via ‘Proof-of-Delivery’, support instant payout upon verification, and brand rug-pulls prevention.
Freelancer Market: Release funds only when services are successfully delivered.
Token OTC Trading: Facilitate over-the-counter crypto trades, crypto to FIAT swaps
And more…

TradeOS is unlocking a massive $4 trillion P2P transaction market while enabling secure and efficient operations for all participants.

2 (1)

Looking Ahead: AI, Meme, and More

TradeOS will soon launch an Omni-chain Meme Trading DEX and an AI auto-trading agent to the Bounty Bay app — with TradeOS protocol as the underlying cross-chain bridgeless infra.

Bounty Bay app is TradeOS’s self-managed marketplace in Telegram. It is designed for P2P online services trading in Telegram, serving 6M traders already and used to partner with many leading Web3 projects, such as OKX, Bybit, HashKey Global, Aethir, UXLink, Carv, Sending Network, QuestN, and GAMEE.

The Revolution for Online Trading

TradeOS is more than just infrastructure; it is the engine driving the next generation of decentralized payment systems. It’s the game-changing solution that unlocks massive potential for Web3 adoption.

Learn more about TradeOS and stay turned for AI Meme trading: X/Twitter: @TradeOS_ai | Website | Litepaper | Telegram News

To view original press release, please visit: https://prbuzz.co/news/1429722/bountybay-labs-unveils-tradeos-the-future-of-decentralized-transactions-with-zktls

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: TradeOS
Email: Send Email
Country: United States
Website: https://www.tradeos.xyz/

Trusted Oregon and Washington Appraisal Company Swift Valuation LLC Launches All-New Website

Clients across the region can now visit the all-new Swift Valuation LLC website to discover the full range of services available and book their free estimates

JANUARY 16, 2025 – The team at trusted appraisal company Swift Valuation LLC is excited to announce the official launch of its all-new website, which offers a seamless online hub where existing and prospective clients in Oregon and Washington State can learn more about the professional appraisals provided by this leading company.

Swift Valuation LLC opened its doors with a mission of providing appraisal services that clients in Oregon and Washington State could trust. Thus far, the company has proven itself with a successful track record of highly satisfied clients across the region. The team at Swift Valuation LLC is passionate about creating and providing credible appraisal reports, precise valuations, and simple processes that leave clients feeling confident about the service they’ve received. “My goal is to make obtaining an accurate valuation of your property an easy, pain-free experience. Let me make the appraisal the least stressful thing on your list,” said the team at Swift Valuation LLC.

Now, Swift Valuation LLC is forwarding its stance as a leader in local appraisals with the launch of an immersive new website where current and curious clients can learn more and book a free estimate. The website demonstrates Swift Valuation LLC’s commitment to its clients with a streamlined, all-in-one hub that offers an in-depth look at its real estate services, which extend to various real estate types including single family homes, duplexes, condos, land, and manufactured homes. Swift Valuation LLC appraises an average of $200 million in real estate each year and knows no bounds when it comes to accurate appraisals, seamlessly navigating even the most complex valuations. As a member of RMLS, NWMLS, and WVMLS, Swift Valuation LLC extends the height of client care and support to its clients at every step of the way.

At the newly launched Swift Valuation LLC website, anyone interested in an Oregon or Washington real estate appraisal can get a full list of the company’s coverage area to answer whether or not they are within the service area. If they are not, they can connect with the team at Swift Valuation LLC by inquiring via the contact section of the new website.

“We offer quality appraisal services with a personal touch,” said a spokesperson for the company. “We encourage anyone in the area to visit our new website now to learn more about the real estate appraisal services that people are talking about.”

Learn more now by visiting www.swift-valuation.com.

ABOUT SWIFT VALUATION LLC

Swift Valuation LLC offers certified residential real estate appraisals in Oregon and Washington State punctuated by the height of professionalism and expertise.

Media Contact
Company Name: Swift Valuation
Contact Person: Ryan Hughes
Email: Send Email
Phone: 503-705-8239
Country: United States
Website: https://www.swift-valuation.com/